Sintilimab

Monoclonal antibody

Also known as IBI308

Approvedregulatory verdict

Evidence outlook

Approved: Tyvyt (sintilimab) with Elunate (fruquintinib): locally advanced or metastatic renal cell... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also approved (5)
CN
  • Tyvyt (sintilimab) with Elunate (fruquintinib): locally advanced or metastatic renal cell carcinomabiospace.com
  • EGFR-mutated non-squamous NSCLC after EGFR-TKI failure, with bevacizumab and chemotherapy (pemetrexed and cisplatin)biospace.com
  • First-line unresectable locally advanced or metastatic squamous NSCLC with gemcitabine and platinum chemotherapyprnewswire.com
  • First-line nonsquamous NSCLC with pemetrexed and platinum chemotherapyprnewswire.com
  • Tyvyt: relapsed or refractory classical Hodgkin's lymphoma after at least two lines of systemic chemotherapy (first NMPA approval)prnewswire.com
Product first approved 2018

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (47)
Non-Small Cell Lung Cancer
NCT05429463 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-12-08 – 2030-08-01 · Squamous Cell Non-small Cell Lung Cancer
What this study did
NCT05116462 · Innovent Biologics (Suzhou) Co. Ltd.
2024-03-15 – 2028-10-14 · Non-Small Cell Lung Cancer
What this study did
NCT06485557 · Tang-Du Hospital
2024-08-01 – 2026-08-01 · Resectable Non-small Cell Lung Cancer
What this study did
NCT05157776 · Tongji University
2021-10-28 – 2025-10-31 · NSCLC, Stage IIIA, EGF-R Negative Non-Small Cell Lung Cancer, ALK Negative NSCLC
What this study did
NCT05648071 · Qianfoshan Hospital
2021-12-01 – 2025-07-01 · Advanced Non-squamous Non-Small-Cell Lung Cancer
What this study did
NCT03802240 · Innovent Biologics (Suzhou) Co. Ltd.
2019-07-11 – 2023-06-30 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT04840290 · Tang-Du Hospital
2019-06-01 – 2023-06-01 · Non Small Cell Lung Cancer
What this study did
NCT03884192 · Shandong Cancer Hospital and Institute
2018-12-12 – 2021-12-30 · Carcinoma, Non-Small Cell Lung
What this study did
NCT03629925 · Innovent Biologics (Suzhou) Co. Ltd.
2018-09-28 – 2021-09-30 · Squamous NSCLC
What this study did
Other / comorbidity
NCT07686796 · Guangdong Provincial People's Hospital
2027-01-01 – 2035-01-01 · Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT, Radiotherapy, Capecitabine, Oxaliplatin
What this study did
NCT07371611 · Qunxing Li,MD
2026-01-01 – 2033-12-31 · Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)
What this study did
NCT07827872 · caohaotian
2026-10-01 – 2032-10-01 · Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
What this study did
NCT07459296 · First Affiliated Hospital of Guangxi Medical University
2026-09-08 – 2032-04-01 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT07917468 · Innovent Biologics (Suzhou) Co. Ltd.
2026-11-25 – 2031-11-24 · Locally Advanced Rectal Cancer
What this study did
NCT05357846 · Sun Yat-sen University
2022-11-01 – 2031-01-31 · Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
What this study did
NCT06925243 · Zuoyi Jiao
2025-04-15 – 2030-12-31 · Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR, ORR,OS,PFS
What this study did
NCT07594340 · Binkui Li
2026-05-15 – 2030-05-30 · Hepatocellular Carcinoma
What this study did
NCT07933679 · Fudan University
2026-11-15 – 2029-12-31 · Early Low Rectal Cancer
What this study did
NCT07016737 · Ye jinjun
2024-08-01 – 2029-09-01 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06584032 · Hutchmed
2024-12-12 – 2029-06-09 · Advanced Endometrial Cancer
What this study did
NCT07692152 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-03-17 – 2029-03 · Anal Squamous Cell Carcinoma, Limited-stage
What this study did
NCT05236972 · Sun Yat-sen University
2022-01-01 – 2028-12-31 · Colorectal Carcinoma
What this study did
NCT07186621 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-07-10 – 2028-11-30 · Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow Margin
What this study did
NCT06497985 · Chipscreen Biosciences, Ltd.
2024-12-06 – 2028-09-30 · Colorectal Cancer
What this study did
NCT05495152 · Henan Cancer Hospital
2022-08-01 – 2028-08-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07306663 · Jiangsu Cancer Institute & Hospital
2021-06-01 – 2028-06-01 · Esophageal Cancer
What this study did
NCT05985798 · Second Affiliated Hospital of Guangzhou Medical University
2023-08-01 – 2027-07-31 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05768503 · Sun Yat-sen University
2023-03-01 – 2027-01 · Metastatic Microsatellite-stable Colorectal Cancer
What this study did
NCT05244798 · Sichuan Cancer Hospital and Research Institute
2022-11-01 – 2026-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05171660 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-02-08 – 2026-12-30 · Colorectal Cancer Stage IV
What this study did
NCT05593458 · Zhejiang University
2023-03-01 – 2026-12 · Locally Advanced Gastric Carcinoma
What this study did
NCT06089369 · Tongji Hospital
2024-06-01 – 2026-11-30 · Hepatocellular Carcinoma
What this study did
NCT06563869 · The First Affiliated Hospital with Nanjing Medical University
2024-02-02 – 2026-11-22 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06089382 · Tongji Hospital
2023-11-01 – 2026-11-01 · Hepatocellular Carcinoma
What this study did
NCT05608200 · Second Affiliated Hospital of Guangzhou Medical University
2022-11-02 – 2026-10-31 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT06161909 · Fujian Medical University Union Hospital
2024-01-10 – 2026-02 · Esophageal Squamous Cell Carcinoma Thoracic Stage II, Esophageal Squamous Cell Carcinoma Thoracic Stage III, Esophageal Squamous Cell Carcinoma Thoracic Stage IV
What this study did
NCT04720716 · Innovent Biologics (Suzhou) Co. Ltd.
2021-02-07 – 2025-12-31 · Hepatocellular Carcinoma
What this study did
NCT03700476 · Sun Yat-sen University
2018-12-21 – 2025-01 · Nasopharyngeal Neoplasms
What this study did
NCT04044222 · Innovent Biologics (Suzhou) Co. Ltd.
2019-10-21 – 2024-12-31 · Classic Hodgkin's Lymphoma
What this study did
NCT04682210 · Sun Yat-sen University
2020-12 – 2024-12 · HCC, Adjuvant Therapy, Immunotherapy
What this study did
NCT03748134 · Innovent Biologics (Suzhou) Co. Ltd.
2018-12-24 – 2023-07-29 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04277663 · Innovent Biologics (Suzhou) Co. Ltd.
2020-04-17 – 2023-02-28 · Acral Melanoma That Has Been Removed by Surgery
What this study did
NCT04675983 · Innovent Biologics (Suzhou) Co. Ltd.
2021-03-10 – 2023-02-12 · Gastric Adenocarcinoma
What this study did
NCT03745170 · Innovent Biologics (Suzhou) Co. Ltd.
2018-12-19 – 2022-10-21 · Gastric Cancer
What this study did
Phase 2/3 (13)
Other / comorbidity
NCT07879586 · Yao Hongwei
2026-10-01 – 2032-10-01 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT07643623 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2026-07-31 – 2031-12-31 · Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07490262 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2026-03-27 – 2030-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05484024 · Chinese Academy of Medical Sciences
2022-08-06 – 2030-07-31 · Rectal Neoplasms Malignant, Radiotherapy
What this study did
NCT06138028 · Qingdao Central Hospital
2023-09-20 – 2026-10-31 · Metastatic Esophageal Squamous Cell Carcinoma
What this study did
NCT05522231 · Hutchmed
2022-10-27 – 2026-08-28 · Advanced Renal Cell Carcinoma
What this study did
NCT05250843 · Third Affiliated Hospital, Sun Yat-Sen University
2022-05-30 – 2024-12-30 · Hepatocellular Carcinoma
What this study did
NCT04167293 · Mian XI
2019-11-16 – 2022-10-31 · Hepatocellular Carcinoma
What this study did
NCT04192682 · Changzhou Cancer Hospital of Soochow University
2019-05-08 – 2021-07-01 · Small Cell Lung Cancer
What this study did
Phase 2 (371)
Non-Small Cell Lung Cancer
NCT07309952 · Yang Hong
2025-12-31 – 2032-10-31 · Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
What this study did
NCT07177105 · Jianxing He
2025-09-10 – 2030-10-01 · Non Small Cell Lung Cancer
What this study did
NCT06221462 · Ningbo No.2 Hospital
2024-02-01 – 2030-02-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07410975 · Shanghai Pulmonary Hospital, Shanghai, China
2026-01-10 – 2030-01-10 · NSCLC Stage II, NSCLC Stage III
What this study did
NCT03872661 · Sun Yat-sen University
2019-03-01 – 2029-12-31 · Lung Cancer Stage III
What this study did
NCT07120698 · Guangdong Association of Clinical Trials
2025-11-05 – 2029-07-26 · NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
What this study did
NCT07603661 · Sun Yat-sen University
2026-06-01 – 2029-06-01 · Non Small Cell Lung Cancer
What this study did
NCT06604351 · Hunan Province Tumor Hospital
2024-09-15 – 2029-05-31 · Non-Small Cell Lung Cancer
What this study did
NCT07014215 · Anhui Provincial Cancer Hospital
2025-06 – 2029-05 · NSCLC (Advanced Non-small Cell Lung Cancer), Resistance to Immunotherapy
What this study did
NCT06962189 · Zhejiang University
2025-05-15 – 2028-12-31 · Non Small Cell Lung Cancer (Stage III)
What this study did
NCT07748325 · Sichuan University
2025-01-10 – 2028-12-30 · Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
What this study did
NCT06688656 · Shanghai Chest Hospital
2025-03-31 – 2028-03-31 · Lung Cancer
What this study did
NCT04728724 · Shanghai Pulmonary Hospital, Shanghai, China
2022-09-10 – 2027-12-31 · Non-small Cell Lung Cancer Stage III
What this study did
NCT07492342 · Jianxing He
2026-01-29 – 2027-12-31 · Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
What this study did
NCT06198907 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-01 – 2027-12 · Non-Small-Cell Lung Cancer
What this study did
NCT04326153 · The First Hospital of Jilin University
2020-03-20 – 2027-12 · IIIA Stage Non-small Cell Lung Cancer
What this study did
NCT06714708 · Anhui Provincial Cancer Hospital
2024-11-20 – 2027-06-01 · NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
What this study did
NCT04836728 · Tianjin Medical University Cancer Institute and Hospital
2021-03-31 – 2026-12-31 · Non-small Cell Lung Cancer Metastatic, First-line Treatment
What this study did
NCT05400070 · Tang-Du Hospital
2021-03-01 – 2026-12-30 · Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
What this study did
NCT06747169 · Jian-Guo Zhou, MD, PhD
2024-12-17 – 2026-12-17 · Squamous Non-Small Cell Lung Cancer SqNSCLC
What this study did
NCT05306847 · Peking Union Medical College Hospital
2022-04-01 – 2026-04-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06479759 · Shanghai Pulmonary Hospital, Shanghai, China
2024-01-12 – 2025-12-12 · NSCLC, PD-1
What this study did
NCT05244213 · Guangdong Provincial People's Hospital
2022-06-04 – 2025-12-01 · Non-small Cell Lung Cancer, EGFR Activating Mutation
What this study did
NCT05004974 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022-04-26 – 2025-09 · Advanced Non Small Cell Lung Cancer
What this study did
NCT05460195 · Shanghai Chest Hospital
2022-01-01 – 2024-12-31 · Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
What this study did
NCT03574402 · Guangdong Association of Clinical Trials
2018-07-09 – 2024-12-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04691388 · Zhejiang Cancer Hospital
2021-03-01 – 2024-12-01 · NSCLC
What this study did
NCT05170581 · The Second Affiliated Hospital of Shandong First Medical University
2021-12-01 – 2024-11-30 · Non-small Cell Lung Cancer
What this study did
NCT04956146 · The First Affiliated Hospital with Nanjing Medical University
2022-02-02 – 2024-09-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04167657 · Peking Union Medical College Hospital
2019-04-15 – 2024-04-30 · Carcinoma, Non-Small Cell Lung
What this study did
NCT04790409 · Zhejiang Cancer Hospital
2019-08-01 – 2023-09-13 · Lung Cancer
What this study did
NCT04486287 · Tianjin Medical University Second Hospital
2020-09-01 – 2023-09-01 · Oligometastasis, Lung Neoplasms
What this study did
NCT04106180 · Fudan University
2019-09-30 – 2023-08-31 · NSCLC Stage IV
What this study did
NCT04459611 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-07-01 – 2023-07-01 · Non-small Cell Lung Cancer
What this study did
NCT04846452 · The First Affiliated Hospital with Nanjing Medical University
2021-06-01 – 2023-05-01 · Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer
What this study did
NCT04612673 · China Medical University, China
2020-11-20 – 2022-12-31 · Non-small Cell Lung Cancer
What this study did
NCT04213170 · Sun Yat-sen University
2019-04-29 – 2022-12 · Brain Metastases, Non Small Cell Lung Cancer, Sintilimab, Bevacizumab
What this study did
NCT03874000 · Tianjin Medical University Cancer Institute and Hospital
2019-03-08 – 2022-06-05 · Non Small Cell Lung Cancer
What this study did
NCT04124731 · Shanghai Chest Hospital
2019-10 – 2022-04 · Carcinoma, Non-small Cell Lung Cancer
What this study did
NCT03798743 · Hunan Province Tumor Hospital
2019-01-01 – 2022-03-01 · Non-small Cell Lung Cancer
What this study did
NCT03765775 · First Hospital of Shijiazhuang City
2018-11-20 – 2021-12-31 · Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm
What this study did
NCT04144582 · Yongchang Zhang
2019-01-01 – 2021-12-31 · Non-small Cell Lung Cancer
What this study did
NCT04371796 · Sichuan Cancer Hospital and Research Institute
2020-05-10 – 2021-12-30 · Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms, Non-small-cell Lung Cancer
What this study did
NCT04252365 · Guangdong Association of Clinical Trials
2020-03-01 – 2021-12-01 · Nsclc
What this study did
Phase 1/2 (40)
Non-Small Cell Lung Cancer
NCT05383482 · Laekna Limited
2022-07-01 – 2024-07-18 · Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma
What this study did
Other / comorbidity
NCT07761286 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-09-30 – 2031-09-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT07714317 · Shanghai Zhongshan Hospital
2026-07-20 – 2030-05-31 · Resectable Hepatocellular Carcinoma
What this study did
NCT07579247 · Shanghai Public Health Clinical Center
2026-05 – 2029-12 · HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic Infection
What this study did
NCT05839275 · Fudan University
2022-08-01 – 2029-07-31 · High-Risk Localized Soft Tissue Sarcoma
What this study did
NCT06888674 · Zhejiang University
2025-04-01 – 2029-04-01 · Pancreatic Cancer Resectable
What this study did
NCT06494943 · Fudan University
2024-06-26 – 2028-12-31 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT07612137 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-01 – 2028-06-30 · Solid Tumor
What this study did
NCT06329973 · Henan Cancer Hospital
2024-02-28 – 2028-06-28 · Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07025889 · Ruijin Hospital
2025-06-02 – 2028-06 · Gastric Cancer
What this study did
NCT06888648 · Zhejiang University
2025-04-01 – 2028-04-01 · Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
What this study did
NCT06956716 · Zhejiang University
2025-04-09 – 2028-04-01 · Advanced Intrahepatic Cholangiocarcinoma
What this study did
NCT06995105 · Zhejiang University
2025-04-09 – 2028-04-01 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT06572813 · First Affiliated Hospital of Zhejiang University
2024-11-15 – 2028-03 · Pancreas Cancer
What this study did
NCT07522411 · BinYong Liang
2026-04-30 – 2028-02 · Hepatocellular Carcinoma
What this study did
NCT05572463 · Innovent Biologics (Suzhou) Co. Ltd.
2022-11-01 – 2027-12-31 · Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
What this study did
NCT06426654 · West China Hospital
2024-06-10 – 2027-08-30 · Gastric Cancer
What this study did
NCT06761027 · Fujian Provincial Hospital
2024-12-23 – 2027-05 · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
What this study did
NCT06195670 · Zhejiang Cancer Hospital
2024-01 – 2027-01 · CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
What this study did
NCT06742411 · West China Hospital
2024-12-31 – 2026-12-31 · Gastric (Stomach) Cancer
What this study did
NCT06391190 · RenJi Hospital
2022-01-01 – 2026-12-30 · Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
What this study did
NCT05640609 · West China Hospital
2023-03-10 – 2026-11-01 · Stomach Neoplasm
What this study did
NCT06759064 · Qilu Hospital of Shandong University
2024-09-12 – 2026-09-01 · Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
What this study did
NCT06220318 · Fujian Haixi Pharmaceuticals Co., Ltd.
2023-07-19 – 2026-08-30 · Solid Tumor
What this study did
NCT06033118 · Sichuan University
2023-10-01 – 2026-08-01 · Combined Hepatocellular Cholangiocarcinoma
What this study did
NCT05632939 · AskGene Pharma, Inc.
2023-02-21 – 2026-02-10 · Gastric Cancer, Gastroesophageal Cancer (GC)
What this study did
NCT06141109 · Xi'an Xintong Pharmaceutical Research Co.,Ltd.
2022-01-18 – 2025-12-31 · Safety Issues, Efficacy, MTD
What this study did
NCT06776757 · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
2023-12-25 – 2025-12-25 · Metastatic Colorectal Cancer
What this study did
NCT05804526 · RemeGen Co., Ltd.
2023-07-19 – 2025-12 · Advanced Solid Tumours
What this study did
NCT04940546 · Sun Yat-sen University
2021-06-16 – 2025-10-30 · Colorectal Cancer Metastatic
What this study did
NCT05457517 · Shanghai YingLi Pharmaceutical Co. Ltd.
2022-09-24 – 2025-01-01 · Advanced Solid Tumors
What this study did
NCT03903705 · Hutchmed
2019-04-25 – 2024-12-16 · Advanced Solid Tumor
What this study did
NCT04636008 · West China Hospital
2020-08-14 – 2024-12 · Anti-PD-1 Antibody, Radiotherapy, Rectal Cancer, MSI-H, Mmr Deficiency
What this study did
NCT05653180 · Innovent Biologics (Suzhou) Co. Ltd.
2023-03-10 – 2024-06-01 · Advanced Biliary Tract Cancer
What this study did
NCT04781413 · Ruijin Hospital
2021-03-01 – 2024-03-01 · Stage IIIC Gastric Cancer
What this study did
NCT04843943 · Fudan University
2021-05-01 – 2023-05-01 · Hepatocellular Carcinoma
What this study did
NCT04840758 · The First Affiliated Hospital of Xiamen University
2021-06 – 2023-04 · Multiple Primary Lung Cancer
What this study did
NCT04202601 · Peking University
2019-12-13 – 2022-12-01 · Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT04567069 · The Second Hospital of Shandong University
2020-09 – 2022-06 · Gastric Cancer
What this study did
NCT03820596 · Huiqiang Huang
2019-03-29 – 2021-11-30 · Safety and Efficacy
What this study did
Phase 1 (48)
Non-Small Cell Lung Cancer
NCT07699757 · Haisco Pharmaceutical Group Co., Ltd.
2026-07 – 2029-11 · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
What this study did
NCT05504278 · Innovent Biologics (Suzhou) Co. Ltd.
2022-09-20 – 2027-07-31 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06431685 · Sichuan University
2024-04-25 – 2026-12-31 · NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
What this study did
NCT05088967 · Innovent Biologics (Suzhou) Co. Ltd.
2021-12-02 – 2023-12-25 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT04672369 · Innovent Biologics (Suzhou) Co. Ltd.
2021-06-06 – 2023-06-01 · Advanced Lung Cancer
What this study did
NCT05118334 · Innovent Biologics (Suzhou) Co. Ltd.
2021-11-12 – 2023-02-17 · NSCLC (Non-small-cell Lung Cancer)
What this study did
NCT04177290 · Innovent Biologics (Suzhou) Co. Ltd.
2020-04-02 – 2022-09-04 · Advanced or Metastatic NSCLC
What this study did
NCT04861948 · Innovent Biologics (Suzhou) Co. Ltd.
2021-05-25 – 2022-07-30 · Solid Tumors, Lung Adenocarcinoma, Osteosarcoma
What this study did
NCT03812549 · Sichuan University
2019-01-18 – 2022-07-08 · Stage IV NSCLC
What this study did
NCT03987867 · Tianjin Medical University Cancer Institute and Hospital
2019-06-01 – 2021-06-01 · Non-small Cell Lung Cancer, First-line Treatment
What this study did
Other / comorbidity
NCT07411781 · Chinese PLA General Hospital
2026-03-01 – 2031-03-01 · Colorectal Cancer, Adult
What this study did
NCT07455617 · Suzhou Abogen Biosciences Co., Ltd.
2026-03-24 – 2030-02 · Advanced / Metastatic Solid Tumor
What this study did
NCT06793956 · Sun Yat-sen University
2025-02-21 – 2030-01-31 · Extranodal Natural Killer/T Cell Lymphoma
What this study did
NCT05363722 · Shanghai Zhongshan Hospital
2025-03-06 – 2029-12 · Hepatocellular Carcinoma
What this study did
NCT07557251 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-08-12 – 2028-12 · Advanced HBV-Related Hepatocellular Carcinoma
What this study did
NCT05427487 · ImmVirx Pty Ltd
2023-02-17 – 2028-11-30 · Colorectal Cancer, Gastric Cancer, Ovarian Cancer
What this study did
NCT07457281 · West China Hospital
2026-04-01 – 2028-06-01 · Head and Neck Squamous Cell Carcinoma HNSCC
What this study did
NCT06773312 · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
2025-02-28 – 2027-04 · Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04906044 · The First Hospital of Jilin University
2021-06-01 – 2026-06-01 · Tislelizumab, Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, PD-1
What this study did
NCT05718219 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2023-03-29 – 2026-04-30 · Advanced Solid Tumors
What this study did
NCT05225116 · Beijing Tsinghua Chang Gung Hospital
2023-01-08 – 2025-12-05 · Hepatocellular Carcinoma
What this study did
NCT06347198 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-04-10 – 2025-05-01 · Metastatic Colorectal Cancer
What this study did
NCT04220944 · Shanghai Zhongshan Hospital
2020-01-01 – 2024-12-30 · Hepatic Carcinoma
What this study did
NCT05164458 · Innovent Biologics (Suzhou) Co. Ltd.
2022-03-22 – 2024-09-30 · Advanced Solid Tumors
What this study did
NCT04085185 · Innovent Biologics (Suzhou) Co. Ltd.
2019-12-04 – 2024-06-30 · Advanced Malignancies
What this study did
NCT04401813 · Innovent Biologics (Suzhou) Co. Ltd.
2020-06-16 – 2024-06-21 · Advanced Hepatocellular Carcinoma
What this study did
NCT04592029 · Second Affiliated Hospital of Guangzhou Medical University
2020-10-21 – 2024-03-17 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT06184841 · Peking University Cancer Hospital & Institute
2020-06-18 – 2023-12-01 · Hepatic Arterial Infusion Chemotherapy, Liver Metastases, Esophageal Squamous Cell Carcinoma
What this study did
NCT05246995 · Shandong Cancer Hospital and Institute
2022-03-23 – 2023-11-23 · Solid Tumor
What this study did
NCT05043298 · Innovent Biologics (Suzhou) Co. Ltd.
2021-10-27 – 2023-08-30 · Advanced Solid Tumor
What this study did
NCT05245916 · Innovent Biologics (Suzhou) Co. Ltd.
2022-04-14 – 2023-08-24 · Advanced Malignancies
What this study did
NCT05119998 · Innovent Biologics (Suzhou) Co. Ltd.
2022-02-08 – 2023-08-08 · Solid Tumor
What this study did
NCT05337267 · Innovent Biologics (Suzhou) Co. Ltd.
2022-04-13 – 2023-07-24 · Healthy Male Subjects
What this study did
NCT04412408 · Shanghai Children's Medical Center
2020-09-01 – 2023-06-30 · Recurrent Stage IV High Risk Neuroblastoma
What this study did
NCT05026593 · Innovent Biologics (Suzhou) Co. Ltd.
2021-09-07 – 2023-06-26 · SCLC
What this study did
NCT04672356 · Innovent Biologics (Suzhou) Co. Ltd.
2021-01-25 – 2023-06-01 · Advanced Lung Cancer
What this study did
NCT03758001 · Innovent Biologics (Suzhou) Co. Ltd.
2019-02-13 – 2023-02-16 · Advanced Solid Tumor
What this study did
NCT04945421 · Innovent Biologics (Suzhou) Co. Ltd.
2021-07-23 – 2023-02-06 · NPC
What this study did
NCT05039658 · Innovent Biologics (Suzhou) Co. Ltd.
2021-09-27 – 2022-12-02 · DLBCL
What this study did
NCT03545971 · Innovent Biologics (Suzhou) Co. Ltd.
2018-09-25 – 2022-08-09 · Advanced Solid Tumors
What this study did
NCT03940001 · Zhejiang Cancer Hospital
2019-05-01 – 2022-05-01 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04104074 · Beijing Tsinghua Chang Gung Hospital
2019-11-25 – 2021-12-31 · Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
What this study did
NCT04400851 · Sun Yat-sen University
2020-08-11 – 2021-12-10 · Pediatric Cancer
What this study did
NCT04427774 · Innovent Biologics (Suzhou) Co. Ltd.
2020-06-29 – 2021-04-27 · Advanced or Metastatic Solid Tumors
What this study did
NCT03568539 · Innovent Biologics (Suzhou) Co. Ltd.
2018-06-27 – 2020-12-07 · Advanced/Metastatic Solid Malignancies
What this study did
NCT04072679 · Chinese Academy of Medical Sciences
2018-10-11 – 2020-11-11 · Advanced Hepatocellular Carcinoma
What this study did
NCT02937116 · Innovent Biologics (Suzhou) Co. Ltd.
2016-10-19 – 2020-09-30 · Cancer, Solid Tumor
What this study did
Phase 4 (6)
Non-Small Cell Lung Cancer
NCT06483009 · Shanghai Chest Hospital
2024-10 – 2027-10 · Non-Small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT05843292 · Shanghai Jiao Tong University School of Medicine
2023-07-01 – 2034-12-31 · Triple-negative Breast Cancer
What this study did
NCT07010393 · Fujian Medical University
2025-07-01 – 2028-12-31 · Thyroid Neoplasms
What this study did
NCT06931808 · First Affiliated Hospital of Ningbo University
2025-03-01 – 2028-08-01 · Localized Advanced Rectal Adenocarcinoma
What this study did
NCT06761911 · Xiuhua Sun
2024-12-31 – 2026-01-31 · Hodgkin Lymphoma (Category)
What this study did
Early phase / not applicable (21)
Non-Small Cell Lung Cancer
NCT06848426 · Jiangxi Provincial People's Hopital
2025-03-10 – 2028-01-31 · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
What this study did
NCT06512207 · Jinzhou Medical University
2023-12-03 – 2026-06 · NSCLC, Stage III, NSCLC, Stage IV
What this study did
NCT04973293 · Ruijin Hospital
2022-10-01 – 2025-12-31 · Lung Neoplasm Malignant
What this study did
Other / comorbidity
NCT07738042 · Tianjin Medical University Cancer Institute and Hospital
2026-07-31 – 2030-12-31 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT07198464 · Zhengzhou University
2025-10-07 – 2029-10-01 · Primary Central Nervous System Lymphoma (PCNSL)
What this study did
NCT07809165 · Beijing 302 Hospital
2026-09 – 2029-09 · Chronic Hepatitis B
What this study did
NCT07542912 · Sun Yat-sen University
2026-06-01 – 2029-06-01 · Complete Remission Rate, CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of Response
What this study did
NCT07474103 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-11-30 – 2028-12-31 · Rectal Cancer, Adenocarcinoma
What this study did
NCT07859410 · Anhui Medical University
2026-10-01 – 2028-10-01 · Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07077798 · Wan-Guang Zhang
2025-08-01 – 2027-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06353646 · Wu Wenming
2024-03-12 – 2026-12 · Pancreatic Cancer
What this study did
NCT05621499 · Tianjin Medical University Cancer Institute and Hospital
2022-12-20 – 2026-12 · Hepatocellular Carcinoma
What this study did
NCT06456515 · The First People's Hospital of Changzhou
2024-05-01 – 2026-03 · Colorectal Cancer Metastatic
What this study did
NCT06457477 · Beijing 302 Hospital
2024-06-15 – 2025-12-15 · Chronic Hepatitis B
What this study did
NCT05940181 · jianming xu
2023-03-01 – 2025-12 · Solid Tumor
What this study did
NCT06070636 · Sun Yat-sen University
2024-05-20 – 2025-06-30 · Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Lenvatinib, Sintilimab
What this study did
NCT04728568 · Beijing Tiantan Hospital
2020-06-01 – 2025-06-01 · Meningioma, Malignant
What this study did
NCT05530785 · Yongchang Zhang
2022-08-01 – 2024-10-01 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05277675 · Southwest Hospital, China
2021-11-01 – 2023-10-30 · Hepatocellular Carcinoma Recurrent
What this study did
NCT04618367 · Sun Yat-sen University
2021-01-01 – 2022-12-30 · Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus
What this study did
NCT04813406 · Henan Provincial People's Hospital
2021-03 – 2022-01 · Esophageal Squamous Cell Carcinoma
What this study did
Used as active comparator (13)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (7)
Non-Small Cell Lung Cancer
NCT06281964 · Avistone Biotechnology Co., Ltd.
2023-12-01 – 2030-06-30 · Non-Small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-10-20 – 2032-09 · Hepatocellular Carcinoma
What this study did
NCT06618664 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-10-28 – 2030-12 · Advanced Hepatocellular Carcinoma
What this study did
NCT07584135 · NingBo Junyan Hongshi Biosciences Co., Ltd
2026-05-28 – 2029-12-31 · Gastric Adenocarcinoma
What this study did
NCT07716449 · Qilu Pharmaceutical Co., Ltd.
2026-09-24 – 2029-08 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07677293 · Peking University
2026-06-26 – 2028-12-31 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05890742 · Innovent Biologics (Suzhou) Co. Ltd.
2023-05-25 – 2028-07-15 · MSI-H
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05976568 · Qilu Pharmaceutical Co., Ltd.
2023-09-01 – 2027-09-01 · Hepatocellular Carcinoma
What this study did
Phase 2 (3)
Non-Small Cell Lung Cancer
NCT06837948 · Shanghai Pulmonary Hospital, Shanghai, China
2025-02-18 – 2031-12-01 · Locally Advanced Non-Small Cell Lung Cancer
What this study did
NCT06620822 · Shanghai Pulmonary Hospital, Shanghai, China
2024-09-30 – 2027-09-30 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07152769 · Fudan University
2025-10-15 – 2028-12-31 · Advanced Intrahepatic Cholangiocarcinoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06530251 · Akeso
2024-09-24 – 2028-09 · Hepatocellular Carcinoma
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06357806 · Beijing 302 Hospital
2024-05-17 – 2026-10-08 · Chronic Hepatitis B
What this study did
Appears in other studies (24)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Non-Small Cell Lung Cancer
NCT05549037 · Hunan Province Tumor Hospital
2022-09-23 – 2026-04-30 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06900218 · Sun Yat-sen University
2025-05-01 – 2033-05-01 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT07537946 · Tongji Hospital
2026-05-30 – 2031-07-30 · Hepatocellular Carcinoma (HCC), Metastases
What this study did
Phase 2/3 (1)
Non-Small Cell Lung Cancer
NCT04702009 · Shanghai Pulmonary Hospital, Shanghai, China
2021-01-20 – 2026-01-20 · Advanced Lung Carcinoma, Non-small Cell Lung Cancer
What this study did
Phase 2 (12)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07646639 · The First Affiliated Hospital with Nanjing Medical University
2026-05-20 – 2030-12-31 · Rectal Cancer, Radiotherapy
What this study did
NCT07832006 · Shunda Du
2025-04-01 – 2030-12-30 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07638501 · Eastern Hepatobiliary Surgery Hospital
2026-06-15 – 2029-06-15 · Biliary Tract Cancer (BTC)
What this study did
NCT06502080 · Shanghai Zhongshan Hospital
2024-07 – 2028-06-30 · Biliary Tract Cancer
What this study did
NCT06860490 · Fudan University
2025-03-18 – 2028-03-10 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06590259 · Shanghai 6th People's Hospital
2024-03-12 – 2027-12 · Colorectal Cancer Liver Metastasis
What this study did
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT06121505 · Sichuan University
2024-03-01 – 2027-02-28 · Lung Squamous Cell Carcinoma
What this study did
NCT04547452 · West China Hospital
2020-07-01 – 2023-07-01 · Stage IV HCC, Immunotherapy, SBRT
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT05979818 · Second Xiangya Hospital of Central South University
2024-11-13 – 2032-12-31 · Non Small Cell Lung Cancer, Propranolol, Immune Checkpoint Inhibitors, Immunotherapy, β-adrenergic Antagonists, Emotional Distress, PD-1 Inhibitors
What this study did
Phase 1 (3)
Non-Small Cell Lung Cancer
NCT03732664 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2018-10-01 – 2023-03-23 · High-Risk Resectable NSCLC
What this study did
Other / comorbidity
NCT05781386 · Jiangsu Simcere Biologics Co., Ltd
2022-03-06 – 2025-12-30 · Advanced Solid Tumor, Cutaneous T Cell Lymphoma
What this study did
NCT03628521 · Shanghai Chest Hospital
2018-07-20 – 2020-12-31 · Lung Cancer, Advanced Stage
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT06549855 · Peking University People's Hospital
2024-09-02 – 2029-10 · Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
What this study did
NCT07067450 · Sichuan University
2025-07-20 – 2026-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06158919 · Fudan University
2023-11-20 – 2026-11-20 · Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
What this study did
NCT05339581 · RenJi Hospital
2022-05-20 – 2024-05-31 · Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sintilimab: this drugPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 86 furthest-along competitors are listed; 527 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(175 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sintilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (25)
November 2026 (2)
Early phase / not applicableHepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT05621499 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT05429463 · CT.gov ↗
What to watch
December 2026 (23)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12 · NCT06198907 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2026-12 · NCT06680115 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Carcinomas (NEC)Not yet recruiting
Est. primary completion 2026-12 · NCT07156019 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2026-12 · NCT05918094 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06714708 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-01 · NCT07268677 · CT.gov ↗
What to watch
Phase 2Peripheral T-cell LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT04512534 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-17 · NCT06747169 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer MetastaticNot yet recruiting
Est. primary completion 2026-12-30 · NCT07007767 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT06031285 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Breast CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07254858 · CT.gov ↗
What to watch
Phase 2Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeRecruiting
Est. primary completion 2026-12-30 · NCT06314334 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-30 · NCT06054906 · CT.gov ↗
What to watch
Phase 3Colorectal Cancer Stage IVActive not recruiting
Est. primary completion 2026-12-30 · NCT05171660 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Cancer, Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06494943 · CT.gov ↗
What to watch
Phase 1/2Gastric (Stomach) CancerRecruiting
Est. primary completion 2026-12-31 · NCT06742411 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1Not yet recruiting
Est. primary completion 2026-12-31 · NCT05998122 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT06555471 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2026-12-31 · NCT06812039 · CT.gov ↗
What to watch
Phase 2NeuroblastomaRecruiting
Est. primary completion 2026-12-31 · NCT06013618 · CT.gov ↗
What to watch
Phase 2Colon AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07468630 · CT.gov ↗
What to watch
Phase 2HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06730373 · CT.gov ↗
What to watch
Phase 2Chronic Hepatitis BRecruiting
Est. primary completion 2026-12-31 · NCT07852091 · CT.gov ↗
What to watch
2027 (74)
January 2027 (1)
Phase 2Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)Recruiting
Est. primary completion 2027-01-15 · NCT07077512 · CT.gov ↗
What to watch
March 2027 (3)
Phase 1/2Locally Advanced Pancreatic Cancer, Metastatic Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06761027 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer, AdultNot yet recruiting
Est. primary completion 2027-03-31 · NCT07411781 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT07492342 · CT.gov ↗
What to watch
April 2027 (7)
Phase 2HCC - Hepatocellular Carcinoma, Conversion TherapyRecruiting
Est. primary completion 2027-04 · NCT07560488 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell Carcinoma HNSCCRecruiting
Est. primary completion 2027-04-01 · NCT07457281 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer ResectableNot yet recruiting
Est. primary completion 2027-04-01 · NCT06888674 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectableNot yet recruiting
Est. primary completion 2027-04-01 · NCT06888648 · CT.gov ↗
What to watch
Phase 1/2Advanced Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-04-01 · NCT06956716 · CT.gov ↗
What to watch
Phase 1/2Advanced Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-04-01 · NCT06995105 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2027-04-30 · NCT06397222 · CT.gov ↗
What to watch
May 2027 (6)
Phase 2Small Cell Lung Cancer Extensive Stage, Resistance to ImmunotherapyNot yet recruiting
Est. primary completion 2027-05 · NCT07022301 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-05 · NCT07014215 · CT.gov ↗
What to watch
Phase 2AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06973330 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagogastric Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-19 · NCT07658872 · CT.gov ↗
What to watch
Phase 2Peritoneal Metastases, Gastric CancerNot yet recruiting
Est. primary completion 2027-05-30 · NCT06213519 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT06421298 · CT.gov ↗
What to watch
June 2027 (9)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-06-01 · NCT06405113 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-06-01 · NCT07584018 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (Diagnosis)Not yet recruiting
Est. primary completion 2027-06-01 · NCT07669740 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06426654 · CT.gov ↗
What to watch
Phase 1/2Solid TumorNot yet recruiting
Est. primary completion 2027-06-30 · NCT07612137 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2027-06-30 · NCT06904014 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2027-06-30 · NCT07040098 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-06-30 · NCT07831993 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06848426 · CT.gov ↗
What to watch
July 2027 (8)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-07 · NCT07025889 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07079410 · CT.gov ↗
What to watch
Phase 2Cervical CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07088731 · CT.gov ↗
What to watch
Phase 3Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow MarginRecruiting
Est. primary completion 2027-07-09 · NCT07186621 · CT.gov ↗
What to watch
Phase 2Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)Not yet recruiting
Est. primary completion 2027-07-10 · NCT07310771 · CT.gov ↗
What to watch
Phase 2Gastric (Stomach) CancerNot yet recruiting
Est. primary completion 2027-07-25 · NCT06748508 · CT.gov ↗
What to watch
Phase 1/2Resectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-07-31 · NCT07714317 · CT.gov ↗
What to watch
Phase 3Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2027-07-31 · NCT05985798 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer …Recruiting
Est. primary completion 2027-08-01 · NCT07061535 · CT.gov ↗
What to watch
Phase 2Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-08-25 · NCT07379424 · CT.gov ↗
What to watch
September 2027 (6)
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2027-09-01 · NCT06204094 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagogastric Juction Cancer, Proficient Mismatch RepairNot yet recruiting
Est. primary completion 2027-09-01 · NCT07621562 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Liver MetastasisRecruiting
Est. primary completion 2027-09-01 · NCT06788171 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell Carcinoma (ESCC)Enrolling by invitation
Est. primary completion 2027-09-01 · NCT07016737 · CT.gov ↗
What to watch
Phase 2Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2027-09-15 · NCT07656766 · CT.gov ↗
What to watch
Phase 2Hepatoid Adenocarcinoma of StomachRecruiting
Est. primary completion 2027-09-20 · NCT07178340 · CT.gov ↗
What to watch
October 2027 (6)
Phase 4Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT06483009 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage IIINot yet recruiting
Est. primary completion 2027-10-01 · NCT05562297 · CT.gov ↗
What to watch
Phase 2Sebaceous Gland CarcinomaNot yet recruiting
Est. primary completion 2027-10-01 · NCT07740993 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-23 · NCT06848569 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT06604351 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-31 · NCT07309952 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Colon Cancer, Rectal CancerNot yet recruiting
Est. primary completion 2027-11 · NCT06652412 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-11-15 · NCT06698757 · CT.gov ↗
What to watch
December 2027 (24)
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT07522411 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07038460 · CT.gov ↗
What to watch
Phase 2BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable), Cetuximab, Dabrafenib, Ipilimumab N01Recruiting
Est. primary completion 2027-12 · NCT07506109 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07179900 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-12-01 · NCT07670026 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-02 · NCT06739161 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2027-12-30 · NCT06220552 · CT.gov ↗
What to watch
Phase 2Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally AdvancedNot yet recruiting
Est. primary completion 2027-12-30 · NCT07018063 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of Small Intestine, Appendix Carcinoma, MetastaticRecruiting
Est. primary completion 2027-12-30 · NCT05472948 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT07748325 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2027-12-31 · NCT06709417 · CT.gov ↗
What to watch
Phase 2Locally Advanced Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06752382 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06962189 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07398326 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophagogastric Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06761846 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07581821 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07521852 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07799077 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-12-31 · NCT07490262 · CT.gov ↗
What to watch
Phase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR …Recruiting
Est. primary completion 2027-12-31 · NCT06925243 · CT.gov ↗
What to watch
Phase 3Early Low Rectal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07933679 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
Early phase / not applicableLocally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07738042 · CT.gov ↗
What to watch
2028 (36)
January 2028 (2)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07774754 · CT.gov ↗
What to watch
Phase 2HCCNot yet recruiting
Est. primary completion 2028-01-20 · NCT07352007 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2NKTCLNot yet recruiting
Est. primary completion 2028-03-06 · NCT07574528 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-03-19 · NCT07487662 · CT.gov ↗
What to watch
Phase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Recruiting
Est. primary completion 2028-03-27 · NCT07518602 · CT.gov ↗
What to watch
Early phase / not applicableRectal Cancer, AdenocarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT07474103 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-04-01 · NCT07515625 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT06313190 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
June 2028 (9)
Phase 2HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06 · NCT07490990 · CT.gov ↗
What to watch
Phase 2Locally Advanced Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06 · NCT07781072 · CT.gov ↗
What to watch
Phase 2Colorectal NeoplasmsNot yet recruiting
Est. primary completion 2028-06-01 · NCT07535632 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07603661 · CT.gov ↗
What to watch
Phase 3Esophageal CancerActive not recruiting
Est. primary completion 2028-06-01 · NCT07306663 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-10 · NCT07410975 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer, Gastric Cancer, Ovarian CancerRecruiting
Est. primary completion 2028-06-30 · NCT05427487 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancers (BTC)Active not recruiting
Est. primary completion 2028-06-30 · NCT07654530 · CT.gov ↗
What to watch
Phase 2Peritoneal Mesothelioma, First-line TherapyNot yet recruiting
Est. primary completion 2028-06-30 · NCT07893340 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Colorectal Neoplasms Malignant, Neoplasm, MetastaticRecruiting
Est. primary completion 2028-07-31 · NCT07722754 · CT.gov ↗
What to watch
Phase 2/3Rectal Neoplasms Malignant, RadiotherapyNot yet recruiting
Est. primary completion 2028-07-31 · NCT05484024 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Pirtobrutinib, Sintilimab, Central Nervous System LymphomaRecruiting
Est. primary completion 2028-08-05 · NCT07416890 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2TNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2028-09-25 · NCT07351487 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-09-30 · NCT07194005 · CT.gov ↗
What to watch
Phase 2ORR,OS,PFSNot yet recruiting
Est. primary completion 2028-09-30 · NCT07328802 · CT.gov ↗
What to watch
October 2028 (5)
Phase 2Gastric AdenocarcinomaRecruiting
Est. primary completion 2028-10 · NCT07263386 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07177105 · CT.gov ↗
What to watch
Phase 2Stomach Neoplasms, Gastric CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07819019 · CT.gov ↗
What to watch
Early phase / not applicableGastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07859410 · CT.gov ↗
What to watch
Phase 2Gastric / Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-20 · NCT07878221 · CT.gov ↗
What to watch
December 2028 (7)
Phase 1Advanced HBV-Related Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07557251 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-12-01 · NCT07331883 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Ovarian Clear Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07239622 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
Phase 2Locally Advanced Gastric CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07638631 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-12-31 · NCT07797816 · CT.gov ↗
What to watch
Phase 4Liver CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07790419 · CT.gov ↗
What to watch
2029 (27)
January 2029 (3)
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01 · NCT05363722 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, BevacizimabRecruiting
Est. primary completion 2029-01 · NCT07324824 · CT.gov ↗
What to watch
Phase 3Advanced Endometrial CancerRecruiting
Est. primary completion 2029-01-08 · NCT06584032 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-02-20 · NCT07492615 · CT.gov ↗
What to watch
March 2029 (2)
Phase 3Anal Squamous Cell Carcinoma, Limited-stageRecruiting
Est. primary completion 2029-03 · NCT07692152 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma Non-resectableRecruiting
Est. primary completion 2029-03-31 · NCT06904183 · CT.gov ↗
What to watch
April 2029 (2)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07699757 · CT.gov ↗
What to watch
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2029-04-10 · NCT07509424 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Hepatocellular Carcinoma (HCC), Bone MetastasesNot yet recruiting
Est. primary completion 2029-05-30 · NCT07537972 · CT.gov ↗
What to watch
June 2029 (4)
Phase 1Advanced / Metastatic Solid TumorRecruiting
Est. primary completion 2029-06 · NCT07455617 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2029-06-01 · NCT07594925 · CT.gov ↗
What to watch
Early phase / not applicableComplete Remission Rate, CRR, Progression Free Survival, Overall Survival, Adverse Event, Duration of ResponseNot yet recruiting
Est. primary completion 2029-06-01 · NCT07542912 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06-26 · NCT07120698 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2029-07-15 · NCT07683221 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung NeoplasmsNot yet recruiting
Est. primary completion 2029-07-31 · NCT07745790 · CT.gov ↗
What to watch
September 2029 (5)
Early phase / not applicableChronic Hepatitis BNot yet recruiting
Est. primary completion 2029-09 · NCT07809165 · CT.gov ↗
What to watch
Phase 2Colon Cancer, PCSK9 Inhibitor, Neoadjuvant ImmunochemotherapyRecruiting
Est. primary completion 2029-09-20 · NCT07840677 · CT.gov ↗
What to watch
Phase 1/2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07761286 · CT.gov ↗
What to watch
Phase 2Mucosal Melanoma, PD-L1 PositiveRecruiting
Est. primary completion 2029-09-30 · NCT07400302 · CT.gov ↗
What to watch
Phase 2Microsatellite Stable Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-09-30 · NCT06841159 · CT.gov ↗
What to watch
October 2029 (3)
Phase 2/3Locally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2029-10-01 · NCT07879586 · CT.gov ↗
What to watch
Phase 2/3Locally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2029-10-01 · NCT07879599 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System Lymphoma (PCNSL)Not yet recruiting
Est. primary completion 2029-10-01 · NCT07198464 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1/2HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic InfectionNot yet recruiting
Est. primary completion 2029-12 · NCT07579247 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted TherapyNot yet recruiting
Est. primary completion 2029-12 · NCT07715565 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07756190 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-31 · NCT03872661 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 3Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT, Radiotherapy, Capecitabine, OxaliplatinNot yet recruiting
Est. primary completion 2030-01-01 · NCT07686796 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Locally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2030-03-25 · NCT07917468 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Nasopharyngeal Carcinoma (NPC)Recruiting
Est. primary completion 2030-04-01 · NCT07459296 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-05-30 · NCT07594340 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07483567 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2MMRd Endometrial Cancer of Stage I~IINot yet recruiting
Est. primary completion 2030-07-20 · NCT07731607 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Advanced Digestive System TumorNot yet recruiting
Est. primary completion 2030-12-31 · NCT07053150 · CT.gov ↗
What to watch
Phase 3Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)Recruiting
Est. primary completion 2030-12-31 · NCT07371611 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
Phase 3Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal CancerRecruiting
Est. primary completion 2031-01-01 · NCT05357846 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2/3Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT07643623 · CT.gov ↗
What to watch
2032 (1)
October 2032 (1)
Phase 3Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral CancerNot yet recruiting
Est. primary completion 2032-10-01 · NCT07827872 · CT.gov ↗
What to watch
2033 (1)
June 2033 (1)
Phase 2Natural Killer/T-cell LymphomaNot yet recruiting
Est. primary completion 2033-06-30 · NCT07768943 · CT.gov ↗
What to watch
2036 (1)
June 2036 (1)
Phase 2Unresectable/Metastatic Gastric CancerNot yet recruiting
Est. primary completion 2036-06 · NCT06365008 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 June 2025Filing acceptedNMPA accepts the NDA for sintilimab plus fruquintinib in renal cell carcinoma
CN, NMPA · HUTCHMED and Innovent Biologics · Source ↗
19 March 2025Topline resultFRUSICA-2 Phase II/III of fruquintinib plus sintilimab meets primary endpoint